Stay updated with breaking news from Refractory Multiple. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- First patient dosed in the Phase 1 clinical trial evaluating ACLX-001 utilizing groundbreaking ARC-SparX technology in relapsed or refractory m...
Cellectis is developing custom TALEN® for Cytovia to develop gene-edited iPSC-derived Natural Killer cellsCytovia and Isleworth Healthcare Acquisition Corp. announce business combination agreementand combined company is expected to be listed
Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics - read this article along with other careers information, tips and advice on BioSpace
Total sales growth of 5.0% to $23.4 Billion with operational growth of 7.7%* and adjusted operational growth of 7.9%* Earnings per share of $1.93 decreasing 16....
Ciltacabtagene autoleucel (cilta-cel), Janssen's first cell therapy, is a structurally differentiated CAR-T with two BCMA-targeting single domain antibodies The Janssen Pharmaceutical Companies of Johnson